Skip to main content
Clinical Trials/NCT02126124
NCT02126124
Completed
Phase 3

A Prospective, Double Blind, Randomized, Controlled Study to Evaluate the Safety and Efficacy of the Deep Transcranial Magnetic Stimulation (DTMS) (With the H-ADD Coil) Intended as an Aid to Smoking Cessation.

Brainsway17 sites in 3 countries224 target enrollmentAugust 20, 2014

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Smoking Cessation
Sponsor
Brainsway
Enrollment
224
Locations
17
Primary Endpoint
Continuous Quit Rate
Status
Completed
Last Updated
5 years ago

Overview

Brief Summary

The purpose of the study is to evaluate the safety and efficacy of DTMS compared to sham treatment as an aid to smoking cessation in chronic, heavy (>10 cigarettes/day) cigarette smokers.

Detailed Description

This is a multi center, randomized, double blind study to evaluate the safety and effectiveness of the device as an aid to smoking cessation. Treatment will be administered over a 6 week period and follow-up assessments will be conducted at 4 months. The clinical study design includes multiple measurements of safety and effectiveness parameters. The design is meant to demonstrate that the device shows superiority compared to sham treatment over six treatment weeks, at the 4 months follow up.

Registry
clinicaltrials.gov
Start Date
August 20, 2014
End Date
November 14, 2019
Last Updated
5 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Brainsway
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Male or female subjects, 22-70 years old.
  • Chronic, heavy (\>10 cigarettes/day) smokers, who smoke for more than 1 year, with no period of abstinence for greater than 3 months during the past year.
  • Subjects who are motivated to quit smoking (with responses "very likely," or "somewhat likely" to the motivation questionnaire).
  • Satisfactory answers on safety screening questionnaire for transcranial magnetic stimulation (Keel 2001).
  • Gave informed consent for participation in the study.

Exclusion Criteria

  • Currently on Nicotine Replacement Therapy (NRT) or smoking cessation drugs (e.g., Zyban, Chantix, etc.) or undergoing behavioral smoking cessation interventions
  • Cognitive or functional disability, diagnosed according to DSM-IV-TR criteria.
  • Active psychiatric disorder according to DSM IV (Axis I and Axis II) criteria within the last year.
  • Current alcohol or other substance abuse or dependence.
  • Alcohol or other substance abuse or dependence during the last 12 months before recruitment.
  • Subject is smoking any other form of tobacco or other substances.
  • Subject is taking psychotropic medications on a regular basis.
  • Subjects with a high risk for severe violence or suicidality as assessed during the screening interview.
  • Subjects who suffer from an unstable physical disease such as high blood pressure (\>150 mmHg systolic / diastolic \> 110 mmHg) or acute, unstable cardiac disease.
  • History of epilepsy or seizure (EXCEPT those therapeutically induced by ECT).

Outcomes

Primary Outcomes

Continuous Quit Rate

Time Frame: 4 week

The primary objective is to compare the four-week continuous quit rate (CQR), representing abstinence during a consecutive 4 week period during the treatment phase, between the two treatment groups.

Secondary Outcomes

  • Number of Cigarettes Smoked Per Day(4 Weeks)

Study Sites (17)

Loading locations...

Similar Trials